To improve the FGF2-based conjugate and overcome potential heterogeneity and resistance of cancer cells to a single-drug treatment, we decided to design FGF2 dual warhead conjugate with two mechanistically different cytotoxic agents: MMAE and α-amanitin. The gene discussed is FGF2; the disease is cancer.